Knee joint arthroplasty in a patient with haemophilia A and high inhibitor titre using recombinant factor VIIa (NovoSeven®): A new case report and review of the literature

Haemophilia

Volumn 7, Issue 3, 2001, Pages 321-326

  Faradji, A ^a   Bonnomet, F ^a   Lecocq, J ^a   Grunebaum, L ^a   Desprez, D ^a   Kern, O ^a   Barbier, L ^a   Sibilia, J ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Haemophilia; Inhibitor; Knee joint arthroplasty; Recombinant factor VIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTHROPATHY; ARTICLE; BLEEDING; CASE REPORT; DATA ANALYSIS; DISEASE SEVERITY; ELECTIVE SURGERY; FOLLOW UP; HEMOPHILIA A; HUMAN; INTRAOPERATIVE PERIOD; KNEE; KNEE ARTHROPLASTY; MEDICAL LITERATURE; MOBILIZATION; ORTHOPEDIC SURGERY; PAIN ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SIDE EFFECT; SURGICAL DRAINAGE; TIME; TREATMENT OUTCOME; WALKING;

ADULT; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD LOSS, SURGICAL; FACTOR VIIA; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; RECOMBINANT PROTEINS;

EID: 0035013792     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00501.x     Document Type: Article

References (32)

1. Cohen I, Heim M, Martinowitz U, Chechick A. Orthopaedic outcome of total knee replacement in haemophilia A. Haemophilia 2000; 6: 104-9.
2. The United States Pharmacopeal Convention Inc. Hemophilia management. Transf Med Rev 1998: 12; 128-40.
3. Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the Knee Society clinical rating system. Clin Orthop 1989; 248: 13-4.
4. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980; 149: 153-9.
5. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7: 78-83.
6. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163-76.
7. Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 1): 118-23.
8. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
9. Schulman S, Bech Jensen M, Varon D et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-6.
10. Schulman S, d'Oiron R, Martinowitz U et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S97-101.
11. Hofmann AA, Plaster RL, Murdock LE. Subvastus (Southern) approach for primary total knee arthroplasty. Clin Orthop 1991; 269: 70-7.
12. White GC, Taylor RE, Blatt PM, Roberts HR. Treatment with a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case. Blood 1983; 62: 141-5.
13. Abildgaard CF, Penner JA, Watson-Williams EJ. Antiinhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980; 56: 978-84.
14. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
15. Brettler DB, Forsberg AD, Levine PH et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149: 1381-5.
16. Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Semin Hematol 1993; 30 (2 (Suppl. 1): 10-21.
17. Nilsson IM, Berntorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 56-9.
18. Bona RD, Pasquale DN, Kalish RI, Witter BA. Porcine factor VIII and plasmapheresis in the management of hemophiliac patients with inhibitors. Am J Hematol 1986; 21: 201-7.
19. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
20. Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII or factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
21. Ménart C, Lalain JJ, Lienhart A, Dechavanne M, Négrier C. Safety and efficacy of three arthroscopic procedures using Holmium: Yag laser in two high-responder haemophiliacs. Haemophilia 1999; 5: 278-81.
22. Heisel MA, Gomperts ED, McComb JG, Hilgartner M. Use of activated prothrombin complex concentrate over multiple surgical episodes in a hemophilic child with an inhibitor. J Pediatr 1983; 102: 951-4.
23. Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
24. Schulman S, Lindstedt M, Alberts KA, Agren PH. Recombinant factor VIIa in multiple surgery. Thromb Haemost 1994; 71: 154 [Letter].
25. O'Marcaigh AS, Schmalz BJ, Shaughnessy WJ, Gilchrist GS. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
26. Vermylen J, Peerlinck K. Optimal care of inhibitor patients during surgery. Eur J Haematol 1998; 63: 15-7.
27. Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, Levi M, Perlinck K. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998; 53: 249-55.
28. Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
29. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
30. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
31. Roberts HR. Clinical experience with activated factor VII. focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S115-8.
32. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 1): S15-20.